Adma Biologics share price today

(ADMA)

Adma Biologics share price is $18.44 & ₹1,581.43 as on 4 Jan 2025, 2.30 'hrs' IST

$18.44

▲

0.47

(2.62%)

Market is closed - opens 8 PM, 06 Jan 2025

View live Adma Biologics share price in Dollar and Rupees. Guide to invest in Adma Biologics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Adma Biologics, along with analyst recommendations, forecasts, and comprehensive financials.

Adma Biologics share price movements

Today's Low: $17.92
Today's High: $18.48
$18.44
2.82%
Downside
Day's Volatility :3.03%
Upside
0.22%
52 Weeks Low: $4.40
52 Weeks High: $23.64
$18.44
76.14%
Downside
52 Weeks Volatility :81.39%
Upside
22.0%

Adma Biologics Returns

Period	Adma Biologics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-8.62%	-8.4%	0.0%
6 Months	58.42%	-3.0%	0.0%
1 Year	283.37%	-0.2%	0.0%
3 Years	808.37%	1.0%	-22.0%

Adma Biologics Key Statistics

in dollars & INR

Previous Close	$17.97
Open	$18.05
Today's High	$18.48
Today's Low	$17.92
Market Capitalization	$4.4B
Today's Volume	$1.9M
52 Week High	$23.64
52 Week Low	$4.4
Revenue TTM	$382.8M
EBITDA	$125.9M
Earnings Per Share (EPS)	$0.27
PE Ratio	68.3
Profit Margin	17.8%
Quarterly Earnings Growth YOY	14.0%
Return On Equity TTM	35.55%

How to invest in Adma Biologics from India?

It is very easy for Indian residents to invest directly in Adma Biologics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Adma Biologics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Adma Biologics or ADMA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Adma Biologics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Adma Biologics shares which would translate to 0.047 fractional shares of Adma Biologics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Adma Biologics, in just a few clicks!

Returns in Adma Biologics for Indian investors in Rupees

Investment Value

₹1,00,000

Adma Biologics investment value today

Current value as on today

₹3,86,532

Returns

₹2,86,532

(+286.53%)

Returns from Adma Biologics Stock

₹2,83,368 (+283.37%)

Dollar Returns

₹3,164 (+3.16%)

Indian investors sentiment towards Adma Biologics

-52.11%

Period: Oct 6, 2024 to Jan 4, 2025. Change in 30 Days versus previous period

Investment in Adma Biologics from India has reduced in the last 30 days as on Jan 5, 2025. -52.11% less purchase transactions for Adma Biologics in the last 30 days versus the previous period.

-54%

Period: Oct 6, 2024 to Jan 4, 2025. Change in 30 Days versus previous period

Search volume for Adma Biologics on INDmoney from India has reduced in the last 30 days as on Jan 5, 2025. -54% less investors are searching Adma Biologics in the last 30 days versus the previous period.

Global Institutional Holdings in Adma Biologics

BlackRock Inc
7.89%
Vanguard Group Inc
7.66%
State Street Corp
5.50%
Amvescap Plc.
5.34%
Morgan Stanley - Brokerage Accounts
3.64%
Nuveen Asset Management, LLC
2.78%

Analyst Recommendation on Adma Biologics

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Adma Biologics(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Adma Biologics

What analysts predicted

Upside of 33.5%

Current:

$18.44

Target:

$24.62

Insights on Adma Biologics

Price Movement
In the last 6 months, ADMA stock has moved up by 64.5%
Increasing Revenue
Revenue is up for the last 18 quarters, 7.78M → 119.83M (in $), with an average increase of 14.6% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -17.64M → 35.90M (in $), with an average increase of 84.8% per quarter

Adma Biologics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$17.0M	↓ 25.37%
Net Income	$-65.7M	↑ 50.24%
Net Profit Margin	-387.06%	↓ 194.8%

	FY19	Y/Y Change
Revenue	$29.3M	↑ 72.79%
Net Income	$-57.0M	↓ 13.23%
Net Profit Margin	-194.37%	↑ 192.69%

	FY20	Y/Y Change
Revenue	$42.2M	↑ 43.85%
Net Income	$-87.6M	↑ 53.57%
Net Profit Margin	-207.5%	↓ 13.13%

	FY21	Y/Y Change
Revenue	$80.9M	↑ 91.72%
Net Income	$-84.5M	↓ 3.6%
Net Profit Margin	-104.34%	↑ 103.16%

	FY22	Y/Y Change
Revenue	$154.1M	↑ 90.36%
Net Income	$-85.2M	↑ 0.86%
Net Profit Margin	-55.29%	↑ 49.05%

	FY23	Y/Y Change
Revenue	$258.2M	↑ 67.59%
Net Income	$-28.2M	↓ 66.85%
Net Profit Margin	-10.94%	↑ 44.35%

	Q2 FY23	Q/Q Change
Revenue	$60.1M	↑ 5.64%
Net Income	$-6.4M	↓ 50.09%
Net Profit Margin	-10.6%	↑ 11.83%

	Q3 FY23	Q/Q Change
Revenue	$67.3M	↑ 11.89%
Net Income	$2.6M	↓ 140.26%
Net Profit Margin	3.81%	↑ 14.41%

	Q4 FY23	Q/Q Change
Revenue	$73.9M	↑ 9.85%
Net Income	$-17.6M	↓ 787.88%
Net Profit Margin	-23.88%	↓ 27.69%

	Q1 FY24	Q/Q Change
Revenue	$81.9M	↑ 10.79%
Net Income	$17.8M	↓ 200.92%
Net Profit Margin	21.75%	↑ 45.63%

	Q2 FY24	Q/Q Change
Revenue	$107.2M	↑ 30.92%
Net Income	$32.1M	↑ 80.06%
Net Profit Margin	29.91%	↑ 8.16%

	Q3 FY24	Q/Q Change
Revenue	$119.8M	↑ 11.8%
Net Income	$35.9M	↑ 12.0%
Net Profit Margin	29.96%	↑ 0.05%

	FY18	Y/Y Change
Profit	$-25.2M	↑ 293.66%

	FY19	Y/Y Change
Profit	$-10.2M	↓ 59.72%

	FY20	Y/Y Change
Profit	$-19.1M	↑ 87.8%

	FY21	Y/Y Change
Profit	$1.2M	↓ 106.15%

	FY22	Y/Y Change
Profit	$35.3M	↑ 2905.68%

	FY23	Y/Y Change
Profit	$88.9M	↑ 152.21%

	Q2 FY23	Q/Q Change
Profit	$16.7M	↑ 1.07%

	Q3 FY23	Q/Q Change
Profit	$24.7M	↑ 47.71%

	Q4 FY23	Q/Q Change
Profit	$30.9M	↑ 25.34%

	Q1 FY24	Q/Q Change
Profit	$38.9M	↑ 25.94%

	Q2 FY24	Q/Q Change
Profit	$57.3M	↑ 47.27%

	Q3 FY24	Q/Q Change
Profit	$59.7M	↑ 4.1%

	FY18	Y/Y Change
Operating Cash Flow	$-62.7M	↑ 68.17%
Investing Cash Flow	$-2.1M	↓ 113.77%
Financing Cash Flow	$42.9M	↓ 29.35%

	FY19	Y/Y Change
Operating Cash Flow	$-76.2M	↑ 21.56%
Investing Cash Flow	$-3.8M	↑ 81.9%
Financing Cash Flow	$80.0M	↑ 86.39%

	FY20	Y/Y Change
Operating Cash Flow	$-102.0M	↑ 33.87%
Investing Cash Flow	$-12.7M	↑ 233.82%
Financing Cash Flow	$143.9M	↑ 79.86%

	FY21	Y/Y Change
Operating Cash Flow	$-112.4M	↑ 10.16%
Investing Cash Flow	$-13.5M	↑ 6.18%
Financing Cash Flow	$121.0M	↓ 15.88%

	FY22	Y/Y Change
Operating Cash Flow	$-59.5M	↓ 47.04%
Investing Cash Flow	$-13.9M	↑ 2.96%
Financing Cash Flow	$108.9M	↓ 10.08%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.1M	↓ 58.85%
Investing Cash Flow	$-872.6K	↓ 55.13%
Financing Cash Flow	$240.1K	↓ 136.91%

Adma Biologics Technicals Summary

Sell

Neutral

Buy

Adma Biologics is currently in a neutral trading position according to technical analysis indicators.

Adma Biologics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Adma Biologics Inc	-4.53%	58.42%	283.37%	808.37%	808.37%
Regeneron Pharmaceuticals, Inc.	-6.48%	-31.75%	-20.46%	20.0%	92.47%
Biontech Se	-2.57%	43.86%	3.49%	-46.08%	167.17%
Alnylam Pharmaceuticals, Inc.	-6.96%	-8.17%	19.03%	55.15%	103.21%
Vertex Pharmaceuticals Incorporated	-11.48%	-15.52%	-2.87%	83.67%	81.92%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Adma Biologics Inc	68.3	68.3	0.0	0.56	0.36	0.2	NA	0.98
Regeneron Pharmaceuticals, Inc.	17.61	17.61	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Adma Biologics Inc	Buy	$4.4B	808.37%	68.3	17.8%
Regeneron Pharmaceuticals, Inc.	Buy	$78.3B	92.47%	17.61	33.61%
Biontech Se	Buy	$27.3B	167.17%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	103.21%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$103.7B	81.92%	32.84	-4.51%

About Adma Biologics

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Organization	Adma Biologics
Employees	624
CEO	Mr. Adam S. Grossman
Industry	Health Technology

Management People of Adma Biologics

Name	Title
Mr. Adam S. Grossman	Co-Founder, President, CEO & Director
Dr. Jerrold B. Grossman D.P.S., Ph.D.	Co-Founder & Vice Chairman of the Board
Mr. Brad Tade	CFO & Treasurer
Ms. Kaitlin Kestenberg	COO & Senior VP of Compliance
Mr. Drew Pantello	Vice President of Marketing & Corporate Development
Mr. John Hafl	Executive Director of Sales
Ms. Cindy Petersen	Vice President of Human Resources
Mr. Skyler Bloom	Senior Director of Business Development & Corporate Strategy

Important FAQs about investing in Adma Biologics from India :

What is Adma Biologics share price today?

Adma Biologics share price today stands at $18.44, Open: $18.05 ; Previous Close: $17.97 ; High: $18.48 ; Low: $17.92 ; 52 Week High: $23.64 ; 52 Week Low: $4.40. The stock opens at $18.05, after a previous close of $17.97. The stock reached a daily high of $18.48 and a low of $17.92, with a 52-week high of $23.64 and a 52-week low of $4.40.

Can Indians buy Adma Biologics shares?

Yes, Indians can invest in the Adma Biologics (ADMA) from India.

With INDmoney, you can buy Adma Biologics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Adma Biologics at zero transaction cost.

How can I buy Adma Biologics shares from India?

It is very easy to buy Adma Biologics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Adma Biologics be purchased?

Yes, you can buy fractional shares of Adma Biologics with INDmoney app.

What are the documents required to start investing in Adma Biologics stocks?

To start investing in Adma Biologics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.